Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14


CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.

Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, Ivanova E, Paweletz CP, Bowden M, Zhou CW, Herter-Sprie GS, Sorrentino JA, Bisi JE, Lizotte PH, Merlino AA, Quinn MM, Bufe LE, Yang A, Zhang Y, Zhang H, Gao P, Chen T, Cavanaugh ME, Rode AJ, Haines E, Roberts PJ, Strum JC, Richards WG, Lorch JH, Parangi S, Gunda V, Boland GM, Bueno R, Palakurthi S, Freeman GJ, Ritz J, Haining WN, Sharpless NE, Arthanari H, Shapiro GI, Barbie DA, Gray NS, Wong KK.

Cancer Discov. 2018 Feb;8(2):216-233. doi: 10.1158/2159-8290.CD-17-0915. Epub 2017 Nov 3.


Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion.

He S, Roberts PJ, Sorrentino JA, Bisi JE, Storrie-White H, Tiessen RG, Makhuli KM, Wargin WA, Tadema H, van Hoogdalem EJ, Strum JC, Malik R, Sharpless NE.

Sci Transl Med. 2017 Apr 26;9(387). pii: eaal3986. doi: 10.1126/scitranslmed.aal3986.


Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.

Bisi JE, Sorrentino JA, Jordan JL, Darr DD, Roberts PJ, Tavares FX, Strum JC.

Oncotarget. 2017 Jun 27;8(26):42343-42358. doi: 10.18632/oncotarget.16216.


Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression.

Bisi JE, Sorrentino JA, Roberts PJ, Tavares FX, Strum JC.

Mol Cancer Ther. 2016 May;15(5):783-93. doi: 10.1158/1535-7163.MCT-15-0775. Epub 2016 Jan 29.


Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.

Roberts PJ, Bisi JE, Strum JC, Combest AJ, Darr DB, Usary JE, Zamboni WC, Wong KK, Perou CM, Sharpless NE.

J Natl Cancer Inst. 2012 Mar 21;104(6):476-87. doi: 10.1093/jnci/djs002. Epub 2012 Feb 1.


Identification of liver receptor homolog-1 as a novel regulator of apolipoprotein AI gene transcription.

Delerive P, Galardi CM, Bisi JE, Nicodeme E, Goodwin B.

Mol Endocrinol. 2004 Oct;18(10):2378-87. Epub 2004 Jun 24.


Impact of PPARgamma overexpression and activation on pancreatic islet gene expression profile analyzed with oligonucleotide microarrays.

Parton LE, Diraison F, Neill SE, Ghosh SK, Rubino MA, Bisi JE, Briscoe CP, Rutter GA.

Am J Physiol Endocrinol Metab. 2004 Sep;287(3):E390-404. Epub 2004 May 4.


PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2.

Yang S, Kuo C, Bisi JE, Kim MK.

Nat Cell Biol. 2002 Nov;4(11):865-70.


Human tumor suppressor ARF impedes S-phase progression independent of p53.

Yarbrough WG, Bessho M, Zanation A, Bisi JE, Xiong Y.

Cancer Res. 2002 Feb 15;62(4):1171-7.


Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function.

Cogswell JP, Brown CE, Bisi JE, Neill SD.

Cell Growth Differ. 2000 Dec;11(12):615-23.


An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers.

Bonham MA, Brown S, Boyd AL, Brown PH, Bruckenstein DA, Hanvey JC, Thomson SA, Pipe A, Hassman F, Bisi JE, et al.

Nucleic Acids Res. 1995 Apr 11;23(7):1197-203.


Strand-invasion of duplex DNA by peptide nucleic acid oligomers.

Peffer NJ, Hanvey JC, Bisi JE, Thomson SA, Hassman CF, Noble SA, Babiss LE.

Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10648-52.


Antisense and antigene properties of peptide nucleic acids.

Hanvey JC, Peffer NJ, Bisi JE, Thomson SA, Cadilla R, Josey JA, Ricca DJ, Hassman CF, Bonham MA, Au KG, et al.

Science. 1992 Nov 27;258(5087):1481-5.


Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line.

Welch DR, Bisi JE, Miller BE, Conaway D, Seftor EA, Yohem KH, Gilmore LB, Seftor RE, Nakajima M, Hendrix MJ.

Int J Cancer. 1991 Jan 21;47(2):227-37.


Supplemental Content

Support Center